The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study
Open accessAbstract
The long-term efficacy and toxicity of hydroxyurea for infants are undefined, and its role in preventing organ dysfunction is unknown. Short-term feasibility of hydroxyurea administration, toxicities, hematologic effects, and effect on spleen function in infants with sickle cell anemia (SCA) were reported (Hydroxyurea Safety and Organ Toxicity [HUSOFT] trial). These infants completing 2 years of hydroxyurea therapy (20 mg/kg/d) were offered study extension with dose escalation to 30 mg/kg/d. Patients were monitored with laboratory tests and biannual imaging studies. Hematologic indices were compared with predicted age-specific values and event rates compared with historic rates. All 21 subjects completing the original trial enrolled in the extension study: median age, 3.4 years old (range, 2.6 to 4.4 years); 12 females; 20 with Hb SS, 1 with Hb S/β0-thalassemia. Seventeen patients completed 4 years of hydroxyurea, and 11 completed 6 years. After 4 years, hydroxyurea was associated with increased hemoglobin concentration, percentage of fetal hemoglobin (Hb F), and mean corpuscular volume (MCV) and decreased reticulocytes, white blood cells (WBCs), and platelets (P < .01). Patients experienced 7.5 acute chest syndrome (ACS) events per 100 person-years, compared with 24.5 events per 100 person-years among historic controls (P = .001). Treated patients had better spleen function than expected and improved growth rates. Infants with SCA tolerate prolonged hydroxyurea therapy with sustained hematologic benefits, fewer ACS events, improved growth, and possibly preserved organ function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
Platt, O. S., Orkin, S. H., Dover, G., Beardsley, G. P., Miller, B., & Nathan, D. G. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111464 · Cited by 535
Gill, F., Sleeper, L., Weiner, S., Brown, A., Bellevue, R., Grover, R., Pegelow, C., & Vichinsky, E. (1995) · Blood · doi:10.1182/blood.v86.2.776.bloodjournal862776 · Cited by 518
Mortality in Sickle Cell Disease
(1994) · New England Journal of Medicine · doi:10.1056/nejm199410133311515 · Cited by 459
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments]
Charache, S., Dover, G., Moore, R., Eckert, S., Ballas, S., Koshy, M., Milner, P., Orringer, E., Phillips, G. J., & Platt, O. (1992) · Blood · doi:10.1182/blood.v79.10.2555.2555 · Cited by 438
Functional Asplenia in Sickle-Cell Anemia
Pearson, H. A., Spencer, R. P., & Cornelius, E. A. (1969) · New England Journal of Medicine · doi:10.1056/nejm196910232811703 · Cited by 425
Kinney, T. R., Helms, R. W., O’Branski, E. E., Ohene‐Frempong, K., Wang, W. C., Daeschner, C., Vichinsky, E. P., Redding‐Lallinger, R., Gee, B. E., Platt, O. S., et al. (1999) · PubMed · Cited by 417
Self-citationFetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea
Steinberg, M. H., Lu, Z.-H., Barton, F. B., Terrin, M. L., Charache, S., Dover, G. J., & Hydroxyurea, T. M. S. O. (1997) · Blood · doi:10.1182/blood.v89.3.1078 · Cited by 407
Pegelow, C. H. (2002) · Blood · doi:10.1182/blood.v99.8.3014 · Cited by 352
Cited by
Wang, W. C., Ware, R. E., Miller, S. T., Iyer, R. V., Casella, J. F., Minniti, C. P., Rana, S., Thornburg, C. D., Rogers, Z. R., Kalpatthi, R. V., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60355-3 · Cited by 803
Self-citationSickle cell disease: old discoveries, new concepts, and future promise
Frenette, P. S., & Atweh, G. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30920 · Cited by 400
How I use hydroxyurea to treat young patients with sickle cell anemia
Ware, R. E. (2010) · Blood · doi:10.1182/blood-2009-04-146852 · Cited by 396
Self-citationHydroxyurea for the Treatment of Sickle Cell Anemia
Platt, O. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0708272 · Cited by 357
Hydroxyurea therapy for sickle cell anemia
McGann, P. T., & Ware, R. E. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1088827 · Cited by 316
Self-citation
Metadata
- Authors
- Hankins, J. S., Ware, R. E., Rogers, Z. R., Wynn, L. W., Lane, P. A., Scott, J. P., & Wang, W. C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2005-10-01
- Volume
- 106
- Issue
- 7
- Pages
- 2269-2275
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2033040678
- Cited by
- 285
- References
- 42
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. https://app.cochat.ai/papers/10.1182/blood-2004-12-4973
- The paper
- Hankins, J. S., Ware, R. E., Rogers, Z. R., Wynn, L. W., Lane, P. A., Scott, J. P., & Wang, W. C. (2005). Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. https://doi.org/10.1182/blood-2004-12-4973
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.